Form 4: MIMEDX Director M. Kathleen Behrens Receives Annual Restricted Stock Grant

M. Kathleen Behrens, a Director at MIMEDX GROUP, INC., acquired 28,609 shares of common stock valued at $6.47 per share as part of her annual restricted stock grant.

Summary

• M. Kathleen Behrens, a Director of MIMEDX GROUP, INC. (MDXG), acquired 28,609 shares of common stock.
• The transaction occurred on June 18, 2025, with a price of $6.47 per share.
• This acquisition represents an annual restricted stock grant to non-employee directors.
• The grant is exempt under SEC Rule 16b-3.
• The awarded shares will vest upon the earlier of 12 months from the grant date or the next annual meeting of shareholders.
• Following this transaction, M. Kathleen Behrens beneficially owns a total of 212,771 shares of MIMEDX common stock.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates an increase in insider ownership, aligning the director's interests with shareholders, even though it's a routine compensation grant rather than an open-market purchase.

Positives

• The acquisition of shares by a director, even as a grant, increases insider ownership, which can align management and shareholder interests.
• The grant is part of a routine compensation structure for non-employee directors, indicating stable corporate governance practices.

Future Outlook

The acquired restricted stock grant is subject to a vesting period, which will occur upon the earlier of 12 months from the grant date or the next annual meeting of shareholders, indicating future full ownership of these shares.

Industry Context

This filing is a routine insider transaction and does not provide specific insights into broader industry trends or competitive landscape, but reflects standard compensation practices for directors in publicly traded companies.

Corporate Governance

Related Party Transactions

• Acquisition of 28,609 shares of common stock by M. Kathleen Behrens, a director of MIMEDX GROUP, INC., as an annual restricted stock grant.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders due to increased equity ownership.
• Employees: No direct impact mentioned.

Next Steps

• Vesting of the 28,609 restricted shares upon the earlier of 12 months or the next annual meeting of shareholders.

Key Dates

Keywords

MIMEDX GROUP, MDXG, SEC Form 4, Insider Transaction, Restricted Stock Grant, Director Compensation, Equity Award, Corporate Governance